Alder BioPharmaceuticals® to Present at Two Upcoming September Investor Conferences
Alder BioPharmaceuticals, Inc.
Aug. 30, 2018
BOTHELL, Wash., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will webcast a business overview and update by Robert W. Azelby, Alder’s president and chief executive officer, at each of the following upcoming healthcare conferences:
-- Wells Fargo 2018 Healthcare Conference at 9:45 a.m. ET on Thursday, September 6, 2018 in Boston, MA. -- Morgan Stanley 16th Annual Global Healthcare Conference at 5:15 p.m. ET on Thursday, September 13, 2018 in New York, NY.
A live audio webcast of each event can be accessed on the Events & Presentations page of the Investors section of Alder's website at http://www.alderbio.com, or by following the link below in your web browser. An archived replay of the webcast will be available on Alder's website for at least 30 days after each live event concludes.
-- Wells Fargo Link: https://cc.talkpoint.com/well001/090518a_as/?entity=63_77EV60U -- Morgan Stanley Link:https://cc.talkpoint.com/morg007/091218a_as/?entity=78_7G4PHJ2
About Alder BioPharmaceuticals, Inc.Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Alder’s lead product candidate, eptinezumab, is a pivotal-stage monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP). Eptinezumab is currently in late-stage clinical development and, if approved, will be the first-to-market infusion therapy for migraine prevention. Alder is also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention. For more information, visit www.alderbio.com.
Investor Relations Contact: Michael SchaffzinStern Investor Relations, Inc.212.362.1200 firstname.lastname@example.org
Media Contact: Ashley CadleTogoRun email@example.com 310.463.0143